Press Release

Publication of Replicor’s first in class HCV entry inhibitor based on its amphipathic DNA polymer technology.

April 23, 2009 – The results of a collaboration between Replicor and the lab of Dr. Jake Liang from the Liver Diseases Branch of the National Institutes of Health (NIH) were published today in the prestigious journal Gastroenterology. This article details the activity of Replicor’s technology against numerous genotypes of HCV in vitro and also its effectiveness in preventing HCV infection in vivo. Click here for publication list.